Crinetics Pharmaceuticals Inc (CRNX) concluded trading on Thursday at a closing price of $29.8, with 0.46 million shares of worth about $13.73 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.19% during that period and on July 03, 2025 the price saw a gain of about 1.22%. Currently the company’s common shares owned by public are about 93.53M shares, out of which, 86.67M shares are available for trading.
Stock saw a price change of -0.63% in past 5 days and over the past one month there was a price change of -7.17%. Year-to-date (YTD), CRNX shares are showing a performance of -35.32% which decreased to -41.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.10 but also hit the highest price of $62.53 during that period. The average intraday trading volume for Crinetics Pharmaceuticals Inc shares is 855.03K. The stock is currently trading -3.45% below its 20-day simple moving average (SMA20), while that difference is down -4.99% for SMA50 and it goes to -28.99% lower than SMA200.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) currently have 93.53M outstanding shares and institutions hold larger chunk of about 104.80% of that.
The stock has a current market capitalization of $2.79B and its 3Y-monthly beta is at 0.33. It has posted earnings per share of -$3.82 in the same period. It has Quick Ratio of 22.53 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRNX, volatility over the week remained 4.29% while standing at 3.61% over the month.
Analysts are in expectations that Crinetics Pharmaceuticals Inc (CRNX) stock would likely to be making an EPS of -1.1 in the current quarter, while forecast for next quarter EPS is -1.17 and it is -4.6 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.22 which is -0.94 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.94 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -21.70% while it is estimated to decrease by -3.07% in next year. EPS is likely to grow at an annualized rate of 4.65% for next 5-years, compared to annual growth of -12.11% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on March 25, 2025 offering a Buy rating for the stock and assigned a target price of $60 to it. On February 04, 2025, Wolfe Research Initiated their recommendations, while on January 22, 2025, Jefferies Upgrade their ratings for the stock with a price target of $55. Stock get a Buy rating from Citigroup on March 06, 2024.
